Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse / Refractory Multiple Myeloma

Multiple Cancer Types

To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse / refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Multiple Myeloma, Phase I
I
Dholaria, Bhagirathbhai
NCT03269136
VICCHEMP1855

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: